Curated News
By: NewsRamp Editorial Staff
July 30, 2025
NanoViricides' NV-387 Offers Hope Against Rising Measles Cases
TLDR
- NanoViricides Inc.'s NV-387 offers a potential first-mover advantage in treating measles, with Orphan Drug and Fast Track designations possibly leading to market exclusivity and accelerated approval.
- NV-387, NanoViricides Inc.'s broad-spectrum antiviral, has demonstrated safety in Phase I trials and efficacy in animal studies, targeting measles amid rising global cases.
- NV-387 by NanoViricides Inc. addresses the critical need for a measles treatment, offering hope to regions with high infection rates and vaccination challenges.
- NanoViricides Inc. is pioneering NV-387, a novel antiviral that could revolutionize measles treatment, currently lacking any approved drugs, amidst record-high global cases.
Impact - Why it Matters
The resurgence of measles in regions with previously high vaccination rates highlights a growing public health crisis. NanoViricides' NV-387 represents a potential turning point, offering a safe and effective treatment option where none currently exists. This development is crucial not only for addressing immediate health concerns but also for mitigating the long-term impacts of measles outbreaks, especially in vulnerable populations. The ability to fast-track NV-387 could save lives and reduce the burden on healthcare systems worldwide.
Summary
NanoViricides, Inc. (NYSE American: NNVC), a leader in the development of broad-spectrum antivirals, has announced a significant breakthrough with its drug candidate NV-387, which could potentially address the alarming rise in measles cases across the United States, Canada, the UK, and the European Union. Having demonstrated effectiveness and safety in animal studies and completed a Phase I clinical trial without adverse events, NV-387 stands out as a promising solution in a landscape where measles cases are surging, with the U.S. reporting 1,319 cases in 2025 alone. The drug's potential for Orphan Drug and Fast Track designations could expedite its approval, offering a much-needed remedy in the face of vaccination challenges and immune dysfunctions. For more details, visit the full press release.
NanoViricides' innovative approach leverages nanomedicine technology to create antiviral therapies, with NV-387 leading its pipeline as a versatile candidate for treating RSV, COVID-19, influenza, and other respiratory infections, alongside MPOX/Smallpox. The company's collaboration with TheraCour Pharma, Inc. underscores its commitment to addressing critical medical needs through advanced nanoviricide technology. With measles cases in Europe reaching their highest since 1997, the urgency for effective treatments has never been greater. Explore more about NanoViricides at www.NanoViricides.com.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, NanoViricides' NV-387 Offers Hope Against Rising Measles Cases
